Literature DB >> 15354735

Expression profiling of colorectal carcinomas using tissue microarrays: cell cycle regulatory proteins p21, p27, and p53 as immunohistochemical prognostic markers in univariate and multivariate analysis.

Friedrich Prall1, Christiane Ostwald, Horst Nizze, Malte Barten.   

Abstract

With the rapidly growing understanding of tumor biology, molecular staging of cancer is expected to improve prognostication. This would be particularly important for cancers amenable to adjuvant treatment, such as colorectal carcinomas. To generate data for this, the tissue microarray technique may prove useful. Tissue microarrays were constructed with triplicate cores (0.6 mm diameter) from the invasive margins of a consecutive single-institution series of 184 colorectal carcinomas. Immunostaining for p53, p21, p27, Ecadherin, and beta-catenin was scored. Tumor cell proliferation was assessed by mitotic indices and Ki-67 labeling, apoptosis by quantification of apoptotic bodies. Reduced nuclear immunostaining for p21 (<10%) and p27 (< or =50%) and reduced membranous expression of Ecadherin were significantly associated with a poorer clinical course by univariate analysis. beta-catenin immunostaining had no prognostic impact. Mitotic and apoptotic indices as well as Ki-67 labeling below the median were indicators of poor prognosis. Complete absence of p53 nuclear staining was a significant adverse prognostic factor. By Cox regression, p53 = 0%, p53 = 0%, in combination with p27 < or = 50%, the mitotic index and the combined mitotic and apoptotic index added prognostic information to UICC stage. The authors found that growth pattern, lymphohistiocytic response, lymphatic permeation, and venous spread, too, each was a strong prognosticator in addition to UICC stage. The results support that tissue microarrays are a useful tool for screening immunohistochemical markers for prognostic use. An immunopanel of p21, p27, and p53 could be useful for prognostication in colorectal carcinoma in addition to UICC stage.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15354735     DOI: 10.1097/00129039-200406000-00003

Source DB:  PubMed          Journal:  Appl Immunohistochem Mol Morphol        ISSN: 1533-4058


  9 in total

1.  A multicenter, phase II study of bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma.

Authors:  Manish A Shah; Derek G Power; Hedy L Kindler; Kyle D Holen; Margaret M Kemeny; David H Ilson; Laura Tang; Marinela Capanu; John J Wright; David P Kelsen
Journal:  Invest New Drugs       Date:  2010-06-25       Impact factor: 3.850

2.  A cohort study of p27 localization in colon cancer, body mass index, and patient survival.

Authors:  Shuji Ogino; Kaori Shima; Katsuhiko Nosho; Natsumi Irahara; Yoshifumi Baba; Brian M Wolpin; Edward L Giovannucci; Jeffrey A Meyerhardt; Charles S Fuchs
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-06       Impact factor: 4.254

3.  p21 expression in colon cancer and modifying effects of patient age and body mass index on prognosis.

Authors:  Shuji Ogino; Katsuhiko Nosho; Kaori Shima; Yoshifumi Baba; Natsumi Irahara; Gregory J Kirkner; Aditi Hazra; Immaculata De Vivo; Edward L Giovannucci; Jeffrey A Meyerhardt; Charles S Fuchs
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-09-01       Impact factor: 4.254

4.  Expression of p21WAF1 in Astler-Coller stage B2 colorectal cancer is associated with survival benefit from 5FU-based adjuvant chemotherapy.

Authors:  Violetta Sulzyc-Bielicka; Pawel Domagala; Elzbieta Urasinska; Dariusz Bielicki; Krzysztof Safranow; Wenancjusz Domagala
Journal:  Virchows Arch       Date:  2011-03-03       Impact factor: 4.064

5.  Assessment of epidermal growth factor receptor (EGFR) expression in primary colorectal carcinomas and their related metastases on tissue sections and tissue microarray.

Authors:  Frédéric Bibeau; Florence Boissière-Michot; Jean-Christophe Sabourin; Sophie Gourgou-Bourgade; Michèle Radal; Frédérique Penault-Llorca; Philippe Rochaix; Laurent Arnould; Marie-Pierre Bralet; David Azria; Marc Ychou
Journal:  Virchows Arch       Date:  2006-07-25       Impact factor: 4.064

6.  Angiodrastic Chemokines in Colorectal Cancer: Clinicopathological Correlations.

Authors:  George Emmanouil; George Ayiomamitis; Adamantia Zizi-Sermpetzoglou; Maria Tzardi; Andrew Moursellas; Argyro Voumvouraki; Elias Kouroumalis
Journal:  Anal Cell Pathol (Amst)       Date:  2018-04-16       Impact factor: 2.916

7.  Increased expression of Ki-67 is a poor prognostic marker for colorectal cancer patients: a meta analysis.

Authors:  Zhao-Wen Luo; Ming-Gu Zhu; Zhi-Qiao Zhang; Feng-Jun Ye; Wen-Heng Huang; Xue-Zhang Luo
Journal:  BMC Cancer       Date:  2019-02-06       Impact factor: 4.430

8.  Thymidylate synthase expression and p21(WAF1)/p53 phenotype of colon cancers identify patients who may benefit from 5-fluorouracil based therapy.

Authors:  Violetta Sulzyc-Bielicka; Pawel Domagala; Dariusz Bielicki; Krzysztof Safranow; Wenancjusz Domagala
Journal:  Cell Oncol (Dordr)       Date:  2013-11-26       Impact factor: 6.730

9.  Clinical significances of p27 in digestive tract cancers: a comprehensive analysis on immunohistochemistry staining, published literatures, microarray and RNA-seq data.

Authors:  Dan-Dan Xiong; Rong-Quan He; Ai-Hua Lan; Wen-Jie Chen; Yi-Huan Luo; Zhi-Hua Ye; Jie Ma; Gang Chen; Yi-Wu Dang
Journal:  Oncotarget       Date:  2018-01-23
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.